FibroGen, Inc. (NASDAQ:FGEN) Sees Large Growth in Short Interest

FibroGen, Inc. (NASDAQ:FGEN) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 4,320,000 shares, a growth of 7.2% from the October 15th total of 4,030,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is currently 3.7 days.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com initiated coverage on FibroGen in a research report on Thursday, November 14th. They set a “hold” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

Hedge Funds Weigh In On FibroGen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alpine Global Management LLC purchased a new stake in FibroGen during the first quarter worth about $25,000. Delap Wealth Advisory LLC acquired a new stake in FibroGen during the first quarter worth approximately $27,000. Geode Capital Management LLC grew its position in shares of FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares during the period. Acadian Asset Management LLC increased its stake in shares of FibroGen by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock valued at $5,883,000 after acquiring an additional 34,937 shares during the last quarter. Finally, Sei Investments Co. raised its stake in FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares during the period. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Stock Performance

NASDAQ FGEN traded down $0.00 on Tuesday, reaching $0.34. The stock had a trading volume of 460,688 shares, compared to its average volume of 2,215,348. The stock has a market cap of $33.86 million, a P/E ratio of -0.27 and a beta of 0.72. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.93. The business’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.70.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same period in the prior year, the firm posted ($0.52) earnings per share. On average, sell-side analysts predict that FibroGen will post -0.86 earnings per share for the current year.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.